Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures

Cellular Immunology

Volumn 273, Issue 1, 2012, Pages 1-9

  Junker, Niels ^a   Kvistborg, Pia ^a   Køllgaard, Tania ^a   Straten, Per Thor ^a   Andersen, Mads Hald ^a   Svane, Inge Marie ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Head neck cancer; Melanoma; T cells; Tumor associated antigens; Tumor infiltrating lymphocytes

Indexed keywords

CYCLIN B1; GAMMA INTERFERON; HLA A ANTIGEN; NY ESO 1 ANTIGEN; OLIGOCLONAL BAND; PROTEIN BCL X; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ADULT; AGED; ALLELE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONE; CELL COMPOSITION; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MALE; MELANOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

ANTIGENS, NEOPLASM; BCL-X PROTEIN; CARCINOMA, SQUAMOUS CELL; CELL COUNT; CELL SURVIVAL; CLONE CELLS; CYCLIN B1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MEMBRANE PROTEINS; STATISTICS, NONPARAMETRIC;

EID: 84856001071     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.12.004     Document Type: Article

References (46)

1. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., Van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
2. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
3. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int. J. Cancer 2010, 127:759-767.
4. Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16:53-65.
5. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest 2007, 117:1147-1154.
6. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., Rogers L.J., Gracia G.J., Jones S.A., Mangiameli D.P., Pelletier M.M., Gea-Banacloche J., Robinson M.R., Berman D.M., Filie A.C., Abati A., Rosenberg S.A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23:2346-2357.
7. Schwartzentruber D.J., Hom S.S., Dadmarz R., White D.E., Yannelli J.R., Steinberg S.M., Rosenberg S.A., Topalian S.L. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 1994, 12:1475-1483.
8. Junker N., Andersen M.H., Wenandy L., Dombernowsky S.L., Kiss K., Sørensen C.H., Therkildsen M.H., von Buchwald C., Andersen E., thor Straten P., Svane I.M. Bimodal ex vivo Expansion of T-cells from patients with Head & Neck Squamous Cell arcinoma: a prerequisite for adoptive cell transfer. Cytotherapy 2011, 13:822-834.
9. Andersen M.H., Pedersen L.O., Capeller B., Brocker E.B., Becker J.C., Thor S.P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001, 61:5964-5968.
10. Andersen M.H., Becker J.C., Thor S.P. The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients. Leukemia 2005, 19:484-485.
11. Andersen M.H., Reker S., Kvistborg P., Becker J.C., Thor S.P. Spontaneous immunity against Bcl-xL in cancer patients. J. Immunol. 2005, 175:2709-2714.
12. Andersen M.H., Svane I.M., Kvistborg P., Nielsen O.J., Balslev E., Reker S., Becker J.C., Straten P.T. Immunogenicity of Bcl-2 in patients with cancer. Blood 2005, 105:728-734.
13. Vonderheide R.H., Hahn W.C., Schultze J.L., Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999, 10:673-679.
14. Wenandy L., Sorensen R.B., Sengelov L., Svane I.M., Thor S.P., Andersen M.H. The immunogenicity of the hTERT540-548 peptide in cancer. Clin. Cancer Res. 2008, 14:4-7.
15. Kao H., Marto J.A., Hoffmann T.K., Shabanowitz J., Finkelstein S.D., Whiteside T.L., Hunt D.F., Finn O.J. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J. Exp. Med. 2001, 194:1313-1323.
16. Andersen R.S., Sorensen R.B., Ritter C., Svane I.M., Becker J.C., Thor S.P., Andersen M.H. Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors. Cancer Immunol. Immunother. 2010.
17. Clark E.A., Golub T.R., Lander E.S., Hynes R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000, 406:532-535.
18. Wenandy L., Sorensen R.B., Svane I.M., Thor S.P., Andersen M.H. RhoC a new target for therapeutic vaccination against metastatic cancer. Cancer Immunol. Immunother. 2008, 57:1871-1878.
19. Caballero O.L., Chen Y.T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009, 100:2014-2021.
20. Kienstra M.A., Neel H.B., Strome S.E., Roche P. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 2003, 25:457-463.
21. Ries J., Mollaoglu N., Vairaktaris E., Neukam F.W., Nkenke E. Diagnostic and therapeutic relevance of NY-ESO-1 expression in oral squamous cell carcinoma. Anticancer Res. 2009, 29:5125-5130.
22. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.R., Appella E., Rosenberg S.A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 1994, 180:347-352.
23. Dudley M.E., Wunderlich J.R., Shelton T.E., Even J., Rosenberg S.A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 2003, 26:332-342.
24. Rodenko B., Toebes M., Hadrup S.R., van Esch W.J., Molenaar A.M., Schumacher T.N., Ovaa H. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat. Protoc. 2006, 1:1120-1132.
25. thor Straten P., Guldberg P., Gronbaek K., Hansen M.R., Kirkin A.F., Seremet T., Zeuthen J., Becker J.C. In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J. Immunol. 1999, 163:443-447.
26. Guldberg P., Guttler F. 'Broad-range' DGGE for single-step mutation scanning of entire genes: application to human phenylalanine hydroxylase gene. Nucleic Acids Res. 1994, 22:880-881.
27. thor Straten P., Kirkin A.F., Siim E., Dahlstrom K., Drzewiecki K.T., Seremet T., Zeuthen J., Becker J.C., Guldberg P. Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture. Clin. Immunol. 2000, 96:94-99.
28. Arden B., Clark S.P., Kabelitz D., Mak T.W. Human T-cell receptor variable gene segment families. Immunogenetics 1995, 42:455-500.
29. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.
30. Dudley M.E., Gross C.A., Langhan M.M., Garcia M.R., Sherry R.M., Yang J.C., Phan G.Q., Kammula U.S., Hughes M.S., Citrin D.E., Restifo N.P., Wunderlich J., Prieto P.A., Hong J.J., Langan R.C., Zlott D.A., Morton K.E., White D.E., Laurencot C., Rosenberg S.A. CD8+ enriched " Young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 2010.
31. Besser M.J., Shapira-Frommer R., Treves A.J., Zippel D., Itzhaki O., Hershkovitz L., Levy D., Kubi A., Hovav E., Chermoshniuk N., Shalmon B., Hardan I., Catane R., Markel G., Apter S., Ben-Nun A., Kuchuk I., Shimoni A., Nagler A., Schachter J. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2010, 16:2646-2655.
32. Benlalam H., Labarriere N., Linard B., Derre L., Diez E., Pandolfino M.C., Bonneville M., Jotereau F. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy. Eur. J. Immunol. 2001, 31:2007-2015.
33. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
34. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
35. Mackensen A., Meidenbauer N., Vogl S., Laumer M., Berger J., Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 2006, 24:5060-5069.
36. Yu M., Zhan Q., Finn O.J. Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol. Immunol. 2002, 38:981-987.
37. Blons H., Laurent-Puig P. TP53 and head and neck neoplasms. Hum. Mutat. 2003, 21:252-257.
38. Sorensen R.B., Andersen R.S., Svane I.M., Engell-Noerregaard L., Hadrup S.R., Balslev E., Andersen M.H., Thor S.P. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clin. Cancer Res. 2009, 15:1543-1549.
39. Dahl C., Guldberg P. The genome and epigenome of malignant melanoma. APMIS 2007, 115:1161-1176.
40. Speiser D.E., Cerottini J.C., Romero P. Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?. Cancer Immun. 2002, 2:14.
41. Parkhurst M.R., Riley J.P., Igarashi T., Li Y., Robbins P.F., Rosenberg S.A. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin. Cancer Res. 2004, 10:4688-4698.
42. Minev B., Hipp J., Firat H., Schmidt J.D., Langlade-Demoyen P., Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl. Acad. Sci. USA 2000, 97:4796-4801.
43. Sorensen R.B., Berge-Hansen L., Junker N., Hansen C.A., Hadrup S.R., Schumacher T.N., Svane I.M., Becker J.C., Thor S.P., Andersen M.H. The immune system strikes back: cellular immune responses against indoleamine 2, 3-dioxygenase. PLoS ONE 2009, 4:e6910.
44. Robbins P.F., Dudley M.E., Wunderlich J., El-Gamil M., Li Y.F., Zhou J., Huang J., Powell D.J., Rosenberg S.A. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 2004, 173:7125-7130.
45. Klebanoff C.A., Khong H.T., Antony P.A., Palmer D.C., Restifo N.P. Sinks Suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005, 26:111-117.
46. Powell D.J., Dudley M.E., Robbins P.F., Rosenberg S.A. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005, 105:241-250.